Aberdeen Group plc Has $64.08 Million Stock Position in Insulet Corporation $PODD

Aberdeen Group plc increased its stake in Insulet Corporation (NASDAQ:PODD) by 45.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 225,429 shares of the medical instruments supplier’s stock after purchasing an additional 70,607 shares during the quarter. Aberdeen Group plc owned approximately 0.32% of Insulet worth $64,076,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of PODD. Vanguard Group Inc. raised its stake in Insulet by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after purchasing an additional 87,845 shares during the period. Federated Hermes Inc. raised its position in Insulet by 14.3% during the second quarter. Federated Hermes Inc. now owns 723,363 shares of the medical instruments supplier’s stock valued at $227,266,000 after buying an additional 90,494 shares during the period. Northern Trust Corp lifted its stake in Insulet by 0.5% in the 3rd quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier’s stock worth $218,945,000 after acquiring an additional 3,618 shares in the last quarter. Marshall Wace LLP boosted its position in Insulet by 4.0% during the 2nd quarter. Marshall Wace LLP now owns 628,568 shares of the medical instruments supplier’s stock worth $197,483,000 after acquiring an additional 24,062 shares during the period. Finally, Qube Research & Technologies Ltd grew its stake in Insulet by 37.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock valued at $177,324,000 after acquiring an additional 156,009 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PODD. Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research note on Thursday, January 22nd. UBS Group reiterated a “buy” rating on shares of Insulet in a report on Thursday, December 18th. Citigroup reduced their price objective on Insulet from $345.00 to $338.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. Raymond James Financial lowered their price objective on shares of Insulet from $385.00 to $355.00 and set an “outperform” rating on the stock in a research note on Thursday, February 19th. Finally, Stifel Nicolaus reduced their price target on shares of Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. Twenty equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $354.24.

Insider Buying and Selling at Insulet

In related news, Director Michael R. Minogue bought 2,030 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was bought at an average cost of $246.23 per share, with a total value of $499,846.90. Following the completion of the purchase, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.39% of the company’s stock.

Insulet Price Performance

Shares of Insulet stock opened at $204.31 on Friday. The stock has a market capitalization of $14.38 billion, a price-to-earnings ratio of 58.37, a P/E/G ratio of 1.22 and a beta of 1.47. The firm’s 50-day moving average price is $238.24 and its two-hundred day moving average price is $284.41. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. Insulet Corporation has a 1-year low of $202.44 and a 1-year high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The company had revenue of $783.80 million for the quarter, compared to analysts’ expectations of $768.31 million. During the same quarter in the prior year, the business earned $1.15 earnings per share. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, equities analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.